

# Rhythm or Rate Control - Still a Conundrum For Clinicians

## THE CHALLENGE



As many as **12 million people in the U.S.** and nearly **18 million in Europe** will have atrial fibrillation (AFib) - the most common cardiac arrhythmia - **by 2060.**



Antiarrhythmic drugs (AADs) **show promise in delaying the progression of AFib and improving quality of life.**



Current U.S. and European Guidelines include AADs as an option for treating patients with new-onset or untreated AFib, **but these recommendations are underused due to clinician concerns about safety, efficacy and monitoring.**



## THE SOLUTION



Get to know the **guidelines!**



Scan the **QR code** for the ACC/AHA/HRS 2019 Update




Scan the **QR code** for the ESC Guideline

Understand the most impactful factors when considering AADs for **early rhythm management**



Stay up-to-date on the latest clinical trials, including:

- **EAST-AFNET 4**
- **CHANGE AFib**
- **EDORA**



Talk to your **patients!**

